Nirmatrelvir/ritonavir and remdesivir against symptomatic treatment in high-risk COVID-19 outpatients to prevent hospitalization or death during the Omicron era: a propensity score-matched study.
Sandra Rajme-LópezBernardo A Martinez-GuerraCarla M Román-MontesKarla M Tamez-TorresAndrea C Tello-MercadoKaren M Tepo-PonceZurisadai Segura-OrtízAbigail López-AguirreOrianlid Del Rocío Gutiérrez-MazariegosOswaldo Lazcano-DelgadilloRafael Nares-LópezMaría F González-LaraDavid Kershenobich-StalnikowitzJosé Sifuentes-OsornioAlfredo Ponce-de-LeónGuillermo M Ruíz-PalaciosPublished in: Therapeutic advances in infectious disease (2024)
In high-risk COVID-19 outpatients, early antiviral treatment with nirmatrelvir/ritonavir or remdesivir was associated with lower 28-day all-cause hospitalization or death.